» Articles » PMID: 15990918

TGF Beta Signalling and Its Role in Tumour Pathogenesis

Overview
Specialty Biochemistry
Date 2005 Jul 2
PMID 15990918
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Transforming growth factor beta (TGF-beta) is a multifunctional cytokine involved in the regulation of cell proliferation, differentiation and survival/or apoptosis of many cells. Knock-out experiments in mice for the three isoforms of TGF-beta have demonstrated their importance in regulating inflammation and tissue repair. TGF-beta is implicated in the pathogenesis of human diseases, including tissue fibrosis and carcinogenesis. TGF-beta receptors act through multiple intracellular pathways. Upon binding of TGF-beta with its receptor, receptor-regulated Smad2/3 proteins become phosphorylated and associate with Smad4. Such complex translocates to the nucleus, binds to DNA and regulates transcription of specific genes. Negative regulation of TGF-beta/Smad signalling may occur through the inhibitory Smad6/7. Furthermore, TGF-beta-activated kinase-1 (TAK1) is a component of TGF-beta signalling and activates stress-activated kinases: p38 through MKK6 or MKK3 and c-Jun N-terminal kinases (JNKs) via MKK4. In the brain TGF-beta, normally expressed at the very low level, increases dramatically after injury. Increased mRNA levels of the three TGF-beta isoforms correlate with the degree of malignancy of human gliomas. TGF-betas are secreted as latent precursors requiring activation into the mature form. TGF-beta may contribute to tumour pathogenesis by direct support of tumour growth and influence on local microenvironment, resulting in immunosuppression, induction of angiogenesis, and modification of the extracellular matrix. TGF-beta1,2 may stimulate production of vascular endothelial growth factor (VEGF) as well as plasminogen activator inhibitor (PAI-I), that are involved in vascular remodelling occurring during angiogenesis. Blocking of TGF-beta action inhibits tumour viability, migration, metastases in mammary cancer, melanoma and prostate cancer model. Reduction of TGF-beta production and activity may be a promising target of therapeutic strategies to control tumour growth.

Citing Articles

Portrait of WWP1: the current state in human cancer.

Lei J, Chen J, Yu W, Wu Q, Jing S, Tang Y Front Cell Dev Biol. 2025; 12:1516613.

PMID: 39949609 PMC: 11821962. DOI: 10.3389/fcell.2024.1516613.


Prognostic Significance and Therapeutic Potential of SERPINE1 in Head and Neck Squamous Cell Carcinoma.

Zhu C, Liu H, Li Z, Shi Y, Zhao J, Bai Y Cancer Med. 2025; 14(2):e70605.

PMID: 39817507 PMC: 11736624. DOI: 10.1002/cam4.70605.


Junctional adhesion molecular 3 (JAM3) is a novel tumor suppressor and improves the prognosis in breast cancer brain metastases via the TGF-β/Smad signal pathway.

Zhu K, Li S, Yao H, Hei J, Jiang W, Martin T J Neurooncol. 2024; 170(2):331-345.

PMID: 39320657 DOI: 10.1007/s11060-024-04797-x.


Role of Elevated Serum TGF-β1 and the Common Promoter -509C/T Polymorphism in the Development and Progression of Primary Glial Tumors and Brain Metastases.

Aleksandrova E, Mindov I, Petrov B, Dimitrova I, Petrov N, Ananiev J Medicina (Kaunas). 2024; 60(1).

PMID: 38256406 PMC: 10819302. DOI: 10.3390/medicina60010146.


Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma.

Trojan A, Lone Y, Briceno I, Trojan J Curr Med Chem. 2023; 31(15):1983-2002.

PMID: 38031775 DOI: 10.2174/0109298673237968231106095141.